SYDNEY, June 15 (Reuters) - Australian liver cancer treatment maker Sirtex Medical Ltd expects its $1.4 billion buyout by a Chinese consortium to will win regulatory approval in Australia and the ...

Agreement includes board position and exclusive negotiation period for further collaborative access to AuroLase® Therapy in other non-U.S. geographies WOBURN, Massachusetts, Sept. 8, 2020 /PRNewswire/ ...

WOBURN, Mass., Nov. 25, 2020 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareholder, ...

Sirtex will support and assist OncoSec with pre-marketing activities for TAVO™ and its visceral lesion applicator (VLA) in exchange for low single-digit royalties on those products. Sirtex is a global ...

Interim CEO unanimously chosen to lead global operations in patient-first oncology innovation WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver ...

The former head of Australian liver-cancer treatment firm Sirtex Medical Ltd has pleaded guilty to insider trading, Australia's corporate regulator said on Wednesday. SYDNEY, July 3 (Reuters) - The ...

SYDNEY/HONG KONG (Reuters) - Chinese private equity firm CDH Investments lobbed a last-minute $1.4 billion offer for Australian liver-cancer treatment firm Sirtex Medical (SRX.AX), trumping Varian ...

Sirtex Medical, an Australian biotech, received an unsolicited $1.41 billion counteroffer from Chinese fund manager CDH Investments. The counteroffer by CDH is a nonbinding, indicative and conditional ...

Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. "This milestone is about more than regulatory approval—it's about giving hope and options back ...

Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin ...

Varian Medical Systems Inc. agreed to buy Australia’s Sirtex Medical Ltd. for about A$1.6 billion ($1.3 billion) in a bid by the U.S. company to add radiation medicine to its portfolio for cancer ...

SAN DIEGO & PENNINGTON, N.J.--(BUSINESS WIRE)--OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today ...